World Next-Generation Sequencing Trends Survey of Laboratories 2017

Dublin, Dec. 05, 2017 -- The "Next-Generation Sequencing Trends: Survey of Laboratories" report has been added to Research and Markets' offering.

The DNA sequencer market has undergone rapid changes in the last few years, continuing its revolutionary trends that hold the promise of bringing major changes to healthcare in the near future. Next-Generation Sequencing Trends: Kalorama Survey of Laboratories aims to identify some of the key changes taking place with both next-generation sequencing (NGS) systems in relation to their usage in labs and in relation to the sequencing of clinical samples for diagnostic or clinical research purposes.

The report includes the following survey results:

• System installations - presents the results in terms of the types of systems installed, the segments and regions where they are found, and other patterns
• Sequencer applications, clinical applications, and usage trends - presents the responses related to the labs' usage of sequencers, in terms of the applications and sample types for which they are run
• Preferences and evaluations - provides the labs' feedback with regard to which features they find important, which aspects of the systems or the process they want improved, and their evaluation of their current sequencer systems
• Future purchase plans - provides the responses related to the labs' plans to purchase sequencers in the near term, along with their views on barriers or issues affecting that

This survey of 78 laboratories was carried out from August to October of 2017. The survey effort targeted labs likely to be doing, or likely to be planning, applications of sequencing in either diagnostic or clinical research settings. Due to the increasing importance of next-generation systems in the market, the scope leans towards these types of sequencers. The mix of labs reached in the survey provides both a range of industry segments as well as groups of labs with both next-generation and capillary systems.

In terms of system installations, the survey presents results in terms of the types of systems installed by model, by region, by industry, and by lab function, including:

• Sequencer Models in Respondents' Labs
• NGS Models in Respondents' Labs, by Region by Percent of Systems (USA, Europe, ROW, Total)
• Installed Base of Next-Generation Systems, Segmented by Industry (Academia, University; Hospital, Medical Center; Independent Reference Lab; Contract Research/ Svcs; Independent Rsch/ Nonprofit; Biotech/ Diagnostics/ Vaccines; Government; Overall)
• NGS Models in Respondents' Labs, by Lab Function (% of Systems) (Research, Service provider (external), Core lab/ shared facility, Diagnostic services/ products)
• Sequencers per Lab, Average, by Lab Function (Overall; Diagnostic services/ products; Core lab/ shared facility; Service provider (external); Research)

In terms of sequencer applications and usage trends, the survey presents the responses related to the labs' usage of sequencers, in terms of the applications and sample types for which they are run. Other areas are covered such as outsourcing and future expectations.

Survey results include:

• NGS Application Volume by Sequencer Model (% of Sequencing)
• Applications Expected to Increase the Most (Resequencing/ amplicon; RNA seq, transcriptomics, gene expr.; Metagenomics; De novo sequencing & whole genome; Exome; Methylation, other epigenetics; ChIP-seq; Small RNA, micro RNA; Expect mostly remain the same)

The survey also provides segmentation of the applications expected to increase, by brand of next-generation system owned:

• Applications Expected to Increase, All Users (Resequencing/ targeted; mRNA-seq / transcriptome; de novo/ whole genome; Metagenomics; Exome; Methylation, other epigenetics; Small/ micro RNA; ChIP-seq)
• Applications Expected to Increase, Illumina Owners
• Applications Expected to Increase, Pac Bio Owners
• Applications Expected to Increase, Thermo Owners
• Applications Expected to Increase, Capillary Owners

The survey provides preferences and evaluations, giving the labs' feedback with regard to the most important criteria for sequencer purchase, including cost of system, cost per sample or run, raw accuracy, ease of use, and other factors.

Further, the survey provides this information with respect to the brand or type of sequencer system owned:

• Most Important Criteria for Purchases, Illumina Owners
• Most Important Criteria for Purchases, Pac Bio Owners
• Most Important Criteria for Purchase, Thermo Fisher Owners
• Most Important Criteria for Purchase, Capillary Owners

The survey finally provides responses related to the labs' plans to for future purchase of sequencers, including the following information:

• Time Frame for Future Purchase (0-6 months, 7-12 months, 1-2 years, Planned but uncertain time frame, No plan)
• Time Frame for Future Purchase, by Brand Owned
• Time Frame for Future Purchase by Type of Lab (Overall, Research, Service provider (ext), Core lab/ shared, Diagnostic svcs/ prod)
• Time Frame for Future Purchase, by Region (USA, Europe, ROW)
• Sequencer Models Likely to Be Considered
• Sequencer Models Likely to Be Considered, by Brand/Type Owned
• Sequencer Models Likely to Be Considered, by Industry/Segment Owned
• Sequencer Models Likely to Be Considered, by Lab Function (Research, Service provider (ext), Core lab, Diagnostics/ clinical, Overall)
• Sequencer Models Likely to Be Considered, by Region (USA, Europe, ROW, Overall)

For more information about this report visit https://www.researchandmarkets.com/research/wbsr5d/nextgeneration

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Molecular Diagnostics